Carcinoma of the Urinary Bladder

Bladder cancer is the commonest malignancy of the urinary tract and a favourite NEET PG topic for linking occupational/chemical carcinogens to surgical oncology. The vast majority are urothelial (transitional cell) carcinomas presenting with painless haematuria, worked up by cystoscopy + TURBT, and managed along the critical divide of non-muscle-invasive vs muscle-invasive disease.

Definition & epidemiology

Carcinoma of the urinary bladder is a malignant neoplasm arising from the urothelium (transitional epithelium) lining the bladder, less commonly from squamous or glandular metaplastic epithelium. It is roughly 3–4 times more common in men, with peak incidence in the 6th–7th decades. The single biggest environmental risk factor globally is cigarette smoking.

The bladder is lined by urothelium that is also present from the renal calyces down to the proximal urethra — hence bladder cancer is part of a "field change" / panurothelial disease, and patients are at risk of synchronous and metachronous tumours anywhere in this tract (calyx, pelvis, ureter, urethra).

High-yield: Urothelium lines the entire tract from renal calyces → renal pelvis → ureter → bladder → proximal urethra. This is why TCC is a field-change disease and the whole tract needs surveillance.

Histological classification

Type	Approx. frequency	Key association
Urothelial (transitional cell) carcinoma (TCC)	~90% (Western world)	Smoking, aniline/aromatic amine dyes, cyclophosphamide, phenacetin
Squamous cell carcinoma (SCC)	~5% (much higher in Egypt)	Schistosoma haematobium, chronic irritation (stones, long-term catheter, chronic UTI)
Adenocarcinoma	~2%	Urachal remnant (dome of bladder), exstrophy, persistent cystitis glandularis
Small cell / neuroendocrine	Rare	Aggressive, treated like small cell lung cancer (chemo)

High-yield: In endemic Egypt/Africa, Schistosoma haematobium is the leading cause and the typical cancer is squamous cell carcinoma, often presenting at a younger age and more advanced stage.

High-yield: Urachal adenocarcinoma arises at the dome/apex of the bladder from urachal remnants and may produce mucin; treatment is partial cystectomy + urachal/umbilical tract excision.

Etiology & risk factors

Bladder carcinogenesis is dominated by carcinogens excreted in and concentrated by the urine, acting on the urothelium over years (long latency).

• Cigarette smoking — the most important and commonest risk factor overall; ~50% of cases in men. Risk is dose-dependent (pack-years) and falls slowly after cessation.
• Occupational aromatic amines (aniline dyes) — β-naphthylamine, benzidine, 4-aminobiphenyl. Workers in dye, rubber, leather, paint, printing, textile, and aluminium industries. Long latency (often >15–20 years).
• Drugs: Cyclophosphamide (its metabolite acrolein causes haemorrhagic cystitis and bladder TCC; uroprotectant MESNA is given to prevent this); phenacetin abuse; pioglitazone (modest signal).
• Chronic irritation/infection: Schistosoma haematobium (→ SCC), long-term indwelling catheter (paraplegics), recurrent stones, chronic UTI.
• Pelvic radiotherapy (e.g. prior cervical/prostate RT).
• Arsenic in drinking water.

High-yield (occupational angle): Aniline dyes → β-naphthylamine / benzidine → bladder TCC. Cyclophosphamide → acrolein → haemorrhagic cystitis + TCC, prevented by MESNA. These exact carcinogen–disease links are repeatedly tested.

Mnemonic for risk factors — "SCAPE-A": Smoking, Schistosoma, Cyclophosphamide, Aniline dyes, Phenacetin, Exstrophy/chronic irritation, Arsenic.

Pathophysiology & molecular basis

Two largely distinct molecular pathways explain the clinical dichotomy:

1. Low-grade, non-invasive papillary tumours → driven by FGFR3 and HRAS mutations → tend to recur but rarely progress to invasion.
2. High-grade, invasive (and CIS) tumours → driven by TP53 and RB loss → high propensity to invade and metastasise.

Carcinoma in situ (CIS) is a flat, high-grade intra-epithelial lesion (not papillary). Though technically non-muscle-invasive, it is aggressive, frequently multifocal, and a strong predictor of progression — hence treated like high-risk disease.

Clinical features

• Painless gross (frank) haematuria — the hallmark and commonest presentation (~80–90%); classically intermittent and total (throughout the stream). Any painless haematuria in an adult >40 is bladder cancer until proven otherwise.
• Irritative symptoms — frequency, urgency, dysuria, especially with CIS or extensive tumour; mimics cystitis but with sterile cultures ("sterile pyuria").
• Suprapubic pain, recurrent UTIs, or clot retention in advanced disease.
• Loin pain / hydronephrosis if tumour obstructs a ureteric orifice.
• Late: pelvic mass, lower-limb oedema (lymphatic/venous obstruction), bone pain, weight loss.

High-yield: Painless, intermittent, total haematuria in an adult is the classic bladder cancer presentation. Persistent irritative LUTS with sterile urine should raise suspicion of CIS.

Diagnosis & investigation of choice

Diagnostic flow:

Painless haematuria → Urine analysis + cytology → CT urography (upper tract imaging) → Cystoscopy (gold standard for diagnosis) → TURBT (provides histology + local staging) → Cross-sectional staging (CT/MRI ± bone scan).

Investigation	Role / notes
Urine cytology	Good sensitivity for high-grade tumours & CIS; poor for low-grade. Non-invasive screening adjunct.
CT urography (CT-IVU)	Imaging investigation of choice for haematuria; evaluates the whole upper tract (synchronous TCC) and shows filling defects.
Flexible/rigid cystoscopy	Gold standard for visualising the bladder tumour and directing biopsy.
TURBT	Both therapeutic (resection) and the key staging step — must include detrusor muscle in the specimen to assess invasion.
MRI pelvis	Best for local T-staging (depth of muscle invasion, perivesical spread).
CT chest/abdomen/pelvis	Nodal and distant metastasis staging in invasive disease.
Bone scan	Only if bone pain or raised alkaline phosphatase.
Urinary tumour markers (NMP22, BTA, FISH/UroVysion)	Adjuncts; not a replacement for cystoscopy.

High-yield: Cystoscopy is the gold standard for diagnosis. CT urography is the imaging of choice for evaluating painless haematuria (assesses entire urothelial tract). TURBT must contain detrusor muscle to stage invasion.

TNM staging (the central concept)

Staging hinges on depth of invasion, which determines the entire treatment algorithm.

Stage	Depth of invasion
Ta	Non-invasive papillary carcinoma (confined to urothelium)
Tis (CIS)	Flat, high-grade carcinoma in situ
T1	Invades subepithelial connective tissue (lamina propria), not muscle
T2	Invades muscularis propria (detrusor) — T2a inner half, T2b outer half
T3	Invades perivesical fat (T3a microscopic, T3b macroscopic mass)
T4	Invades adjacent organs — prostate/uterus/vagina (T4a) or pelvic/abdominal wall (T4b)

Nodes: N1 single true-pelvic node, N2 multiple pelvic nodes, N3 common iliac nodes. M1 distant metastasis.

The crucial divide:

• Non-muscle-invasive bladder cancer (NMIBC) = Ta, Tis, T1 (~75% at presentation) — managed by TURBT ± intravesical therapy, bladder preserved.
• Muscle-invasive bladder cancer (MIBC) = T2 and above — needs radical cystectomy (± neoadjuvant chemotherapy) or bladder-preservation chemoradiation.

High-yield: Memorise the line — muscle invasion (≥T2) = radical cystectomy territory; everything below (Ta/Tis/T1) is bladder-sparing TURBT + intravesical therapy.

Management

A. Non-muscle-invasive bladder cancer (Ta, Tis, T1)

1. Complete TURBT — resect all visible tumour with muscle in the base.
2. Single immediate post-op intravesical chemotherapy (e.g. mitomycin C or epirubicin within 24 h) for low-risk tumours to reduce recurrence.
3. Risk stratification → intravesical maintenance therapy:
   • Low risk (solitary, low-grade, small Ta): TURBT + single instillation; surveillance.
   • Intermediate/High risk (high-grade, T1, CIS, multifocal, recurrent, large): Intravesical BCG (induction + maintenance).
4. Re-TURBT in 2–6 weeks for high-grade/T1 or if no muscle in first specimen.

Intravesical BCG (Bacillus Calmette–Guérin)

• A live attenuated Mycobacterium bovis vaccine instilled into the bladder; works via a non-specific local immune/inflammatory (Th1) response that destroys tumour cells.
• Most effective intravesical agent, and the treatment of choice for CIS and high-risk NMIBC; reduces both recurrence and progression.
• Started ≥2 weeks after TURBT (avoid BCG sepsis through raw resected surface).
• Contraindications: gross haematuria, traumatic catheterisation, active TB, immunosuppression, within 2 weeks of TURBT.
• Side effects: cystitis/irritative symptoms (common), flu-like illness; serious — BCG sepsis / disseminated BCGosis (treat with anti-tubercular drugs ± steroids).
• BCG-unresponsive disease → consider early radical cystectomy.

High-yield: Intravesical BCG is the treatment of choice for carcinoma in situ (CIS) and high-risk NMIBC; it is the most effective intravesical agent and must be delayed ≥2 weeks after TURBT to avoid BCG sepsis.

B. Muscle-invasive bladder cancer (≥T2, no metastases)

Treatment flow: Confirmed ≥T2 → Neoadjuvant cisplatin-based chemotherapy → Radical cystectomy + pelvic lymph node dissection + urinary diversion.

• Radical cystectomy is the gold-standard curative treatment:
  • Men: removal of bladder, prostate and seminal vesicles (cystoprostatectomy).
  • Women: anterior exenteration — bladder, urethra, uterus, fallopian tubes, ovaries, and anterior vaginal wall.
  • Plus bilateral pelvic lymphadenectomy.
• Neoadjuvant cisplatin-based chemotherapy (e.g. MVAC — methotrexate, vinblastine, doxorubicin/adriamycin, cisplatin; or gemcitabine + cisplatin) improves survival before cystectomy.
• Bladder-preservation (trimodality therapy) — maximal TURBT + chemoradiation — for selected patients unfit for or declining cystectomy.

Urinary diversion after cystectomy

Diversion	Description	Notes
Ileal conduit (Bricker)	Ureters anastomosed to an isolated ileal segment → cutaneous stoma with external bag	Simplest, most common, incontinent diversion
Continent cutaneous pouch	Detubularised bowel reservoir, catheterisable stoma	Patient self-catheterises
Orthotopic neobladder	Bowel reservoir anastomosed to native urethra	Near-normal voiding; needs intact, tumour-free urethra

High-yield: The classic urinary diversion after radical cystectomy is the ileal conduit (Bricker's operation) — an incontinent diversion using a segment of ileum.

High-yield: Use of bowel for diversion can cause a hyperchloraemic (hypokalaemic) metabolic acidosis — most marked with the older ureterosigmoidostomy (also predisposes to colonic adenocarcinoma at the anastomosis).

C. Metastatic / advanced disease

• First line: cisplatin-based combination chemotherapy (gemcitabine + cisplatin or MVAC).
• Immunotherapy: checkpoint inhibitors (PD-1/PD-L1, e.g. pembrolizumab, atezolizumab) for cisplatin-ineligible or platinum-refractory disease.
• Antibody–drug conjugates (enfortumab vedotin), FGFR inhibitors (erdafitinib for FGFR-altered tumours) in later lines.

Complications

• Recurrence — the defining feature of NMIBC (hence lifelong cystoscopic surveillance).
• Progression to muscle-invasive disease (especially high-grade T1, CIS).
• Clot retention and recurrent haematuria/anaemia.
• Ureteric obstruction → hydronephrosis → obstructive uropathy / renal failure.
• Metastasis — pelvic nodes, then lung, liver, bone.
• Treatment-related: BCG sepsis; post-cystectomy complications (ileus, anastomotic leak, stoma issues); metabolic acidosis and electrolyte disturbance, B12 deficiency, and stones with bowel diversions.

Key differentials

• Other causes of painless haematuria: renal cell carcinoma, upper-tract TCC, urolithiasis, BPH, glomerulonephritis (IgA nephropathy), papillary necrosis, schistosomiasis.
• Irritative LUTS / sterile pyuria: bacterial/TB cystitis, CIS, interstitial cystitis, prostatitis.
• Bladder filling defect on imaging: blood clot, fungal ball, stone, ureterocele, endometriosis, malakoplakia.
• Tumour mimics: nephrogenic adenoma, cystitis glandularis/cystica, inflammatory pseudotumour.

Painless haematuria — quick localiser	Clue
Glomerular	Dysmorphic RBCs, red cell casts, proteinuria
Bladder TCC	Total haematuria, clots, irritative LUTS, smoker/dye worker
RCC	Loin mass, paraneoplastic features, varicocele (left)
Stone	Colicky loin-to-groin pain (usually not painless)

Recently asked / exam angle

• Occupational carcinogen matching: β-naphthylamine / benzidine / aniline dyes → bladder TCC; dye, rubber, leather industry workers. Frequently asked as one-liners.
• Schistosoma haematobium → squamous cell carcinoma of the bladder (Egypt) — classic single-best-answer.
• Cyclophosphamide → acrolein → haemorrhagic cystitis + TCC; prevented by MESNA.
• Investigation of choice / gold standard: cystoscopy (diagnosis), CT urography (haematuria work-up), TURBT must include detrusor muscle.
• Treatment of CIS / high-risk NMIBC = intravesical BCG (most effective agent; delay ≥2 weeks post-TURBT; mechanism = local immune response).
• Muscle-invasive (≥T2) = radical cystectomy + ileal conduit (Bricker); neoadjuvant cisplatin-based chemo improves survival.
• Urachal adenocarcinoma at the dome.
• Ureterosigmoidostomy → hyperchloraemic metabolic acidosis + colonic adenocarcinoma risk.
• Image-based: cystoscopic appearance of a papillary tumour; CT showing bladder mass/filling defect.

Rapid revision

1. Commonest bladder cancer = urothelial (transitional cell) carcinoma; commonest risk factor = smoking.
2. β-naphthylamine, benzidine, 4-aminobiphenyl (aniline dyes) → occupational bladder TCC, long latency.
3. Schistosoma haematobium → squamous cell carcinoma (Egypt); urachal remnant → adenocarcinoma at the dome.
4. Cyclophosphamide → acrolein → haemorrhagic cystitis + TCC; prevent with MESNA.
5. Classic presentation = painless, intermittent, total gross haematuria; CIS = irritative LUTS with sterile urine.
6. Cystoscopy = gold standard diagnosis; CT urography = imaging of choice; TURBT specimen must contain detrusor muscle for staging.
7. Staging divide: Ta/Tis/T1 = NMIBC (TURBT + intravesical therapy) vs ≥T2 = MIBC (radical cystectomy).
8. Intravesical BCG = treatment of choice for CIS and high-risk NMIBC; works via local immune response; start ≥2 weeks after TURBT; watch for BCG sepsis.
9. Single immediate post-TURBT instillation of mitomycin C reduces recurrence in low-risk tumours.
10. Radical cystectomy: men = bladder+prostate+seminal vesicles; women = anterior exenteration; + pelvic lymphadenectomy. Standard diversion = ileal conduit (Bricker).
11. Neoadjuvant cisplatin-based chemo (MVAC / gem-cis) improves survival in muscle-invasive disease; checkpoint inhibitors for advanced/refractory disease.
12. Bowel urinary diversion (esp. ureterosigmoidostomy) → hyperchloraemic hypokalaemic metabolic acidosis + colonic adenocarcinoma risk.